Navigation Links
ADVENTRX Announces 9-Month Stability Data Results for ANX-530
Date:6/30/2010

fer materially from historical results or those expressed or implied by such forward-looking statements.  These risks and uncertainties include, but are not limited to: the risk that future stability testing results are not consistent with prior results or are out-of-specification or otherwise do not support comparability between ADVENTRX's prior and intended commercial manufacturing sites or a commercially-viable expiration dating period; the risk that the FDA does not accept a submitted Exelbine NDA for review, including as a result of identifying clinical or nonclinical reasons for a refusal-to-file or identifying CMC reasons that were not identified in the refusal-to-file of the previously submitted Exelbine NDA; ADVENTRX's dependence on the success of Exelbine, and uncertainty as to whether Exelbine will receive regulatory approval or be commercialized successfully; the risk that the bioequivalence data and other information included in the Exelbine NDA may not adequately support bioequivalence with Navelbine®; the potential that changes made in transferring the manufacturing process for Exelbine may result in a lack of comparability between the commercial product and the material used in the bioequivalence trial, and that the FDA may require ADVENTRX to perform additional nonclinical, bioequivalence or clinical studies; the potential for the FDA to impose other requirements to be completed before or after approval of the Exelbine NDA; the risk that ADVENTRX will pursue development activities at levels or on timelines, or will incur unexpected expenses, that shortens the period through which its operating funds will sustain it; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ADVENTRX Added to Russell Microcap Index
2. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference on May 17
3. ADVENTRX Pharmaceuticals Announces Closing of Financing
4. ADVENTRX Reverse Split Effective; Trading on Adjusted Basis Begins Today
5. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2009 Financial Results
6. ADVENTRX Receives Brand Name Acceptance for ANX-530
7. ADVENTRX Receives Refuse to File Letter from FDA on ANX-530 New Drug Application
8. ADVENTRX Announces Management Promotions
9. ADVENTRX Appoints Icahn Representative to Board of Directors
10. ADVENTRX Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference on February 9
11. ADVENTRX Pharmaceuticals to Present at the Lippert/Heilshorn Life Sciences Virtual Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Sept. 16, 2014  This report analyzes the worldwide markets ... provides separate comprehensive analytics for the US, Canada ... , Asia-Pacific , Middle ... Rest of World. Annual estimates and forecasts are provided for ... is provided for these markets. Market data and analytics are ...
(Date:9/16/2014)... Sept. 16, 2014  Denovo Biopharma, LLC, today ... oncology drug, from Eli Lilly and Company (NYSE: ... and commercialize enzastaurin globally, including transfer of all ... Lilly developed enzastaurin in a ... Phase 3 clinical trials for diffuse large B-cell ...
(Date:9/16/2014)... Resources Group finds that the rheumatoid arthritis (RA) disease-modifying antirheumatic drug ... billion in 2023 in the United States , ... Italy , Spain , the ... TNF-alpha inhibitors will remain the leading drug class in both sales ... constrained and patient shares will decline due to the uptake of ...
Breaking Medicine Technology:Global Digital Radiography Industry 2Global Digital Radiography Industry 3Global Digital Radiography Industry 4Global Digital Radiography Industry 5Global Digital Radiography Industry 6Global Digital Radiography Industry 7Global Digital Radiography Industry 8Global Digital Radiography Industry 9Global Digital Radiography Industry 10Global Digital Radiography Industry 11Global Digital Radiography Industry 12Global Digital Radiography Industry 13Global Digital Radiography Industry 14Global Digital Radiography Industry 15Global Digital Radiography Industry 16Global Digital Radiography Industry 17Global Digital Radiography Industry 18Global Digital Radiography Industry 19Global Digital Radiography Industry 20Global Digital Radiography Industry 21Global Digital Radiography Industry 22Denovo Biopharma Acquires Late-Stage Oncology Drug From lilly For Development As A Personalized Medicine 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 3
... KineMed Inc., a,pathway-based drug discovery and development ... of an investigational agent,to regenerate nerve cells in ... cognition and mood. The agent, part of a ... a behavioral test in a,preclinical model. The findings ...
... am ET, BEDMINSTER, N.J., Oct. 11 ... top-line results from,the company,s Phase 3 study of ... 83 patients with short bowel,syndrome (SBS) received either ... dose (0.10 mg/kg/day) or placebo. The,clinical efficacy endpoint ...
Cached Medicine Technology:KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model 2KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model 3Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 2Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 3Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 4Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 5Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 6Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 7
(Date:9/16/2014)... 17, 2014 Keep that sexy decolletage as ... the neck. , "The Face Whisperer Neck & Decollete ... Kathy Heshelow, founder of Sublime Beauty®. "It contains rich ingredients ... MSM and arnica." , A special ingredient is Argireline, known ... The rich anti-aging cream comes in an airless pump bottle, ...
(Date:9/16/2014)... Today, Zane Benefits, the #1 ... transitioning employees to individual health insurance. , ... Act (ACA) in full effect, many small and ... all of their employees towards individual health insurance. ... plans, coverage for pre-existing conditions, and premium tax ...
(Date:9/16/2014)... UWDress.com, the well-known wedding dress manufacturer and ... assortment online. Additionally, the firm has launched a ... big discounts now, up to 62 percent off. ... charming; it has won a lot of positive reviews ... is also providing big savings on many other items, ...
(Date:9/16/2014)... (September 16th, 2014; San Francisco) In a ... increasingly weighed against potential benefit, a Yale study ... or less-aggressive radiation procedures on elderly women with ... be presented at the 56th annual conference of ... Francisco. (Abstract 131: Evaluating National Practice in Radiotherapy ...
(Date:9/16/2014)... Recently, iFitDress.com, one of the most famous dress suppliers in ... gown collection. According to the company’s sales manager, all ... to 69% off) at present. Additionally, all the company’s old ... a frequent caller of your site. I like your products ... quite happy. All items are of good quality. I sincerely ...
Breaking Medicine News(10 mins):Health News:15% Off Face Whisperer® Neck & Decollete Cream Now from Sublime Beauty; Care For This Delicate Skin That Shows Age Quickly 2Health News:Zane Benefits Publishes New Information on Transitioning Employees to Individual Health Insurance 2Health News:New Elegant Evening Wear Assortment Released By UWDress.com 2Health News:iFitDress.com: One Shoulder Evening Gown Collection Unveiled Online 2
... between Uttar Pradesh Government Railway Police and Junior doctors ... Meerut by Meerut Nauchandi Express lead to injuring medicos ... the police personnel occupying the reserved seats of the ... seven state medical colleges for three days ordering enquiry ...
... appearing in the January 18 issue of The Journal of ... when adult neurons try to undergo division. This finding in ... development of the disease. ,"If you could ... from dying prematurely. This could be a fresh approach to ...
... are of the opinion that interstellar dust coming into our ... significance. The results have exceeded all expectations, according to Donald ... principal investigator, or lead scientist, for Stardust. ‘It's a huge ... ones, there are small ones’, he said. ...
... medicines will no longer be available to Canadians from supermarkets ... are aimed at preventing addicts from making crystal meth. //The ... be affected by the ban which will come into force ... sell about 15 medicines which are of the single ingredient ...
... masala and tobacco products near hospitals and educational institutions by the ... from beyond 500 meters from such institutions, according to the new ... that this is strictly adhered to. ,The youth ... product due its low price and easy availability. Children are also ...
... call to bedside phones cost higher than the call made ... charges levied on the bedside phones. // ... complaining of the bedside phone charges. ,The company ... the peak time costed around 49p per minute and at ...
Cached Medicine News:Health News:Dividing Nerve Cells Could Trigger Alzheimer's Disease 2Health News:Ofcom To Assess The Bedside Call Charges 2
For the quantitative in vitro determination of Aspartate Aminotransferase (AST) in serum and plasma....
Enzymatic Clearance assay for the in vitro quantitative determination of HDL-cholesterol in human serum and plasma....
Enzymatic Clearance assay for the in vitro quantitative determination of HDL-cholesterol in human serum and plasma....
This is an Immunological assay intended for the quantitative in vitro determination of haemoglobin A1c (HbA1c) in whole blood....
Medicine Products: